Hepion Pharmaceuticals (NASDAQ:HEPA) announced a restructuring that, among other things, will suspend the enrollment of new patients in the Phase 2b ‘ASCEND-NASH’ clinical trial of its lead drug candidate, rencofilstat...
Hepion Pharmaceuticals (NASDAQ:HEPA) presented new data from its Phase 2 ALTITUDE-NASH trial demonstrating that 17 weeks of rencofilstat treatment significantly reduced liver stiffness in subjects with advanced F3...
Hepion Pharmaceuticals (NASDAQ:HEPA) published a new research study in mice where rencofilstat prevented the growth of human hepatitis C virus (“HCV”)-associated liver tumors. HCV-infected mice developed small liver...
Hepion Pharmaceuticals (NASDAQ:HEPA) entered into a securities purchase agreement with a healthcare-focused institutional investor for the purchase of 980,393 shares of the company at a purchase price of $5.10 per share...
Hepion Pharmaceuticals (NASDAQ:HEPA) reported new research findings that discovered a mechanism by which the company’s lead drug candidate, rencofilstat, may exert anti-cancer activity. The research examined...
Hepion Pharmaceuticals (NASDAQ:HEPA) reported positive findings from a translational research study assessing the effects of rencofilstat on lung tissue obtained from patients with idiopathic pulmonary fibrosis (IPF)...
Hepion Pharmaceuticals (NASDAQ:HEPA) will present two abstracts for poster presentations at the European Association for the Study of the Liver (EASL) International Liver Congress 2023 taking place June 21 – 24 in...
A data and safety monitoring board (DSMB) has reviewed the current data for Hepion Pharmaceuticals’ (NASDAQ:HEPA) ASCEND-NASH Phase 2b trial with rencofilstat and issued a “study may proceed without modification”...
Hepion Pharmaceuticals (NASDAQ:HEPA) will outline the integration of its artificial intelligence and machine learning platform, AI-POWR, into all aspects of its clinical pharmacological programs at the 2023 Canadian...
Analysts for Cantor Fitzgerald and Brookline Capital Markets gave high marks to Hepion Pharmaceuticals’ (NASDAQ:HEPA) Phase 2a ATTITUDE NASH trial results, which met its primary and secondary endpoints as well as showed...